PDC and neoplasm: Notably, no difference in the amount of activated CX-2009 PDC and Probody therapeutic CX-191 was detected at either 110 or 510 μg, as follows: 2.00 ± 0.86 ng/mg versus 2.34 ± 0.96 ng/mg of tumor tissue, respectively, at 110 μg; and 10.42 ± 4.93 ng/mg versus 10.01 ± 2.42 ng/mg of tumor tissue, respectively, at 510 μg.